Figure legends
Figure 1 Post-marketing data of tyrosine kinase inhibitor (TKI)-associated cardiac toxicities in the FAERS database
FAERS, Food and Drug Administration’s Adverse Event Reporting System; TKI, tyrosine kinase inhibitor.
Figure 2 Reporting odds ratios (RORs) of TKI-induced cardiac AEs. The graph presents the RORs of each cardiac adverse events(AEs) compared to reports in the full database. A lower limit of the ROR 95% CI above 1 is considered signifcant. (a):Sorafenib;(b): Lenvatinib; (c):Regorafenib;(d):Cabozantinib
*CI values exceeded graph limits.
&:only the top 20 repored PT were listed.
#:some of the RORs were too big to be presented
AE,adverse events; TKI, tyrosine kinase inhibitor.
Figure 3 Time to event onset of TKI-induced cardiac AEs. (a):Hypertension; (b):Cardiac failure; (c):Atrial fibrillation; (d):Acute myocardial infarction; (e):Acute coronary syndrome;
AE,adverse events; TKI, tyrosine kinase inhibitor.
Table 1. Summary of FDA-approved TKIs for HCC